Finch Therapeutics Group Inc FNCH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.49
- Day Range
- $2.24–2.65
- 52-Week Range
- $1.86–16.74
- Bid/Ask
- $2.15 / $2.63
- Market Cap
- $3.69 Mil
- Volume/Avg
- 53,342 / 47,187
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.49
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1
Valuation
Metric
|
FNCH
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.16 |
Price/Sales | 34.49 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
FNCH
|
---|---|
Quick Ratio | 6.15 |
Current Ratio | 6.33 |
Interest Coverage | — |
Quick Ratio
FNCH
Profitability
Metric
|
FNCH
|
---|---|
Return on Assets (Normalized) | −29.84% |
Return on Equity (Normalized) | −61.60% |
Return on Invested Capital (Normalized) | −34.73% |
Return on Assets
FNCH
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zcrvrvbgrs | Ksh | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nprlvjlq | Wczpr | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wjjgssc | Vpzqqrw | $103.7 Bil | |
MRNA
| Moderna Inc | Bvqqwftf | Vjj | $47.9 Bil | |
ARGX
| argenx SE ADR | Ntdmxrfrg | Hqjjn | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Yljyrrzf | Bmjh | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rsjwckxmt | Xxcyp | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Rwzbzsgz | Kvrjqzp | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Clhpvdhkt | Rqxbhb | $12.8 Bil | |
INCY
| Incyte Corp | Ztkdvvbvp | Zbytlpk | $12.1 Bil |